CJC-1295 plus Ipamorelin remains the most widely used growth hormone secretagogue stack in the peptide community, and for good reason: it is the most targeted way to boost endogenous GH production without the cost, side effects, or legal exposure of exogenous growth hormone. In 2026, the stack occupies an unchanged regulatory position — not on the PCAC agenda, not on the Category 2 list, and sitting in the gray area that defines most of the research peptide market.
⚡ Key Takeaway
CJC-1295 + Ipamorelin is a growth hormone secretagogue stack that stimulates your body’s own GH production rather than injecting exogenous growth hormone. CJC-1295 extends the GH release window while Ipamorelin provides a clean, selective GH pulse. Neither is FDA-approved for human use.
How the Stack Works
Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. What makes it preferred over older GH secretagogues is its selectivity — it triggers GH release without significantly raising cortisol or prolactin, two hormones that older compounds like GHRP-6 and GHRP-2 elevated as an unwanted side effect. The GH pulse from Ipamorelin mimics your body’s natural pulsatile release pattern rather than producing the flat, sustained elevation that exogenous GH injections create.
CJC-1295 is a growth hormone releasing hormone (GHRH) analog that extends the duration of the GH release signal. Where Ipamorelin triggers the pulse, CJC-1295 extends the window during which that pulse is active. The combination produces both a stronger and longer GH elevation than either compound alone, while maintaining the pulsatile pattern that avoids the side effects of constant GH elevation.
The DAC (Drug Affinity Complex) variant of CJC-1295 extends the half-life to approximately 6-8 days, allowing less frequent dosing. The non-DAC version (CJC-1295 without DAC, sometimes called Mod GRF 1-29) has a shorter half-life of roughly 30 minutes, requiring more frequent administration but producing a more physiologic pulsatile pattern.
What GH Secretagogues Actually Do for You
Growth hormone influences recovery, body composition, sleep quality, connective tissue maintenance, and skin health. The effects of GH secretagogue use are typically more subtle and gradual than what exogenous GH produces, because you are augmenting endogenous production rather than replacing it with supraphysiologic doses.
Realistic expectations from a CJC-1295 + Ipamorelin protocol: improved sleep quality (particularly deep-sleep phases, since GH and deep sleep are bidirectionally linked), gradual improvement in recovery between training sessions, modest body composition shifts toward leaner body mass over 3-6 months, improved skin elasticity and quality, and better connective tissue resilience. These are maintenance and optimization effects, not transformative changes. Men expecting GH secretagogues to produce the dramatic fat loss or muscle gain of exogenous GH at bodybuilding doses will be disappointed.
The 2026 Legal Reality
CJC-1295 is listed on the FDA’s Category 1 list as a compound that cannot be compounded under section 503A — it is explicitly excluded, not merely unreviewed. This means that unlike BPC-157 or TB-500, there is no pending regulatory pathway to make CJC-1295 legally prescribable through compounding pharmacies. It is not on the July PCAC agenda and is not expected to be nominated in the foreseeable future.
Ipamorelin occupies a different but similarly restricted position. It has not been placed on either the Category 1 or Category 2 lists, leaving it in regulatory limbo — not explicitly prohibited from compounding but not explicitly permitted either.
The practical reality: the CJC-1295 + Ipamorelin stack remains a research-peptide-only option. If you are looking for a legally prescribed GH-supporting peptide, tesamorelin is the FDA-approved alternative (see our tesamorelin article). If you are using research-grade, the standard quality controls apply: verified third-party COAs, reputable vendors, and understanding of the legal framing.